生物医药ETF（512290）连续3日迎净流入，制药行业表现较好

Core Viewpoint - The biopharmaceutical ETF (512290) has seen net inflows for three consecutive days, indicating strong performance in the pharmaceutical sector [1] Industry Summary - The pharmaceutical industry is performing well, with several significant developments: - Heng Rui Medicine's Aisuda (JAK1) has submitted a new indication application for market approval [1] - Innovent Biologics' first original IL-23p19 monoclonal antibody in China has been approved for market [1] - BeiGene's application for Sotolacra has been accepted by the FDA in the U.S. and granted priority review status [1] - CanSino Biologics' Cadonilimab has been included as a "preferred option" for first-line treatment of advanced cervical cancer in the NCCN guidelines (China version) [1] - Novo Nordisk's Amycretin diabetes phase II clinical data has been released, while the phase III trial of Semaglutide for Alzheimer's disease has failed [1] - The results of the second round of IRA negotiations in the U.S. have been announced [1] - BioNTech has updated clinical data on PD-L1/VEGFTNBC [1] ETF Summary - The biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, and medical devices from the Shanghai and Shenzhen markets [1] - The index aims to reflect the overall performance of listed companies related to biotechnology and healthcare, showcasing high growth potential and innovation within the biopharmaceutical industry [1]